Company: ARTL
Filing Date: 2025-09-05
Form Type: 8-K
Source: 0001640334-25-001642
Chunk: 0

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-09-05
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

On September 4, 2025, Artelo Biosciences, Inc. (the “ Company”) entered into an Underwriting Agreement (the “ Underwriting Agreement”) with R. F. Lafferty & Co., Inc., the sole book-running manager and underwriter (the “ Underwriter”), relating to an underwritten offering (the “ Offering”) of (i) 640,924 shares (the “ Shares”) of common stock, par value $0.001 per share, of the Company (the “ Common Stock”) at a price to the public of $4.40 per share (the “ Share Purchase Price”), and (ii) pre-funded warrants to purchase up to 40,894 shares of Common Stock at an exercise price of $0.001 per share (the “ Pre-funded Warrants” and together with the Shares, the “ Securities”) at a price to the public of $4.399 per Pre-funded Warrant, for aggregate gross proceeds of approximately $3,000,000, before deducting underwriting discounts and commissions and the other estimated Offering expenses. Pursuant to the Underwriting Agreement, the Company has granted the Underwriter a 45-day option to purchase up to an additional 102,272 shares of Common Stock at the Share Purchase Price per share, less the underwriting discounts to cover over-allotments, if any.

Each Pre-funded Warrant is exercisable for one share of our Common Stock, with an exercise price equal to $0.001 per share, are immediately exercisable and terminate once exercised in full. A holder of Pre-funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% (the “ Ownership Limitation”) of the number of shares of the Company’s Common Stock outstanding immediately after giving effect to such exercise. A holder of Pre-funded Warrants may increase or decrease the Ownership Limitation by providing at least 61 days’ prior notice to the Company.

The Offering was closed on September 5, 2025 (the “ Closing Date”). The Company delivered the Securities to the Underwriter on the same day.

The Company intends to use the net proceeds from the Offering to advance its product candidates through preclinical and clinical development, including manufacturing, research and technical development, clinical studies, capital expenditures, and for working capital and general corporate purposes.

The Underwriting Agreement contains customary representations, warranties and covenants